Magazine Article | March 1, 2023

Companies To Watch: Hummingbird Bioscience

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Joining the forces of computation and systems biology to fight cancer and autoimmune disease

Hummingbird Bioscience has built its own platform, dubbed Rational Antibody Discovery (RAD), to discover a pipeline of precision therapeutics under development for treating cancer and autoimmune diseases. RAD combines AI tools and systems biology that guide the creation of antibodies to bind with critical functional regions of the proteins triggering disease. The platform has yielded three different agents for solid tumors and one targeting autoimmunity and cancer. Two lead drugs, coded HMBD-001 and HMBD-002, are in Phase 1 trials for solid tumors. Two other cancer drugs, HMBD-501 and HMBD-011, have entered preclinical testing, and two earlier- stage programs are in discovery.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader